Aims/hypothesis The aims of this work were to assess glycaemic control in metformin users receiving their first add-on glucose-lowering therapy and to examine the real-life effectiveness of different add-on drugs. Methods We carried out a population-based cohort study using healthcare databases in northern Denmark during 2000-2012. We included 4,734 persons who initiated metformin monotherapy and added another glucose-lowering drug within 3 years. Attainment of recommended HbA 1c goals within 6 months of add-on was investigated, using Poisson regression analysis adjusted for age, sex, baseline HbA 1c , diabetes duration, complications and Charlson Comorbidity Index. Results Median metformin treatment duration at intensification was 12 months (interquartile range [IQR] 4-23 months) and pre-intensification HbA 1c was 8.0% (IQR 7.2-9.2%) (64 mmol/mol). Median HbA 1c dropped 1.2% (13 mmol/mol) with a sulfonylurea (SU) add-on, 0.8% (9 mmol/mol) with a dipeptidyl peptidase-4 (DPP-4) inhibitor, 1.3% (14 mmol/mol) with a glucagon-like peptide-1 (GLP-1) receptor agonist, 0.9% (10 mmol/mol) with other non-insulin drugs and 2.4% (26 mmol/mol) with insulin. Compared with SU add-on, attainment of HbA 1c <7% (<53 mmol/mol) was higher with GLP-1 receptor agonists (adjusted RR [aRR] 1.10; 95% CI 1.01, 1.19) and lower with DPP-4 inhibitors (aRR 0.94; 95% CI 0.89, 0.99), other drugs (aRR 0.86; 95% CI 0.77, 0.96) and insulin (aRR 0.88; 95% CI 0.77, 0.99). The proportion of metformin add-on users who attained HbA 1c <7% (<53 mmol/mol) increased from 46% in 2000-2003 to 59% in 2010-2012, whereas attainment of HbA 1c <6.5% (<48 mmol/mol) remained 30% among patients aged <65 years without comorbidities. Conclusions/interpretation Among early type 2 diabetes patients receiving their first metformin add-on treatment, HbA 1c reduction with different non-insulin drugs is similar to, and comparable with, that observed in randomised trials, yet 41% do not achieve HbA 1c <7% (<53 mmol/mol) within 6 months.
Introduction
Metformin monotherapy is currently the recommended initial glucose-lowering drug (GLD) for most patients with type 2 diabetes, with addition of a second GLD if HbA 1c targets are not achieved. Glucose-lowering treatment options have expanded considerably [1] yet the number of head-to-head trials comparing GLDs is limited and there is little evidence to guide clinicians' choice of add-on therapy [2] . Adding a non-insulin second-line GLD to metformin was found to reduce HbA 1c levels by approximately 1% in clinical trials [3] and an individualised treatment approach following metformin initiation is currently recommended [4] . In real-world type 2 diabetes populations, who may differ from clinical trial participants in some characteristics (e.g. age, comorbidities and compliance with medications [5] ), little is known about success rates when older and newer GLDs are used to intensify metformin therapy.
We aimed to assess the quality of glycaemic control in a large population-based cohort of incident metformin users receiving their first add-on glucose-lowering therapy. We examined the association of calendar time with achieved glycaemic control and compared the reduction of HbA 1c for different add-on GLDs.
Methods
Setting and study population We conducted this cohort study in northern Denmark during 2000-2012. We used linkage of existing population-based medical databases covering 1.8 million inhabitants or 30% of Denmark's population, as described in more detail elsewhere [6] . The cohort included individuals who redeemed a first-time GLD prescription (codes A10A, A10B) of metformin monotherapy (no GLD prescription other than metformin within the first 14 days) between 1 January 2000 and 31 December 2012 and who had at least 12 months of baseline data. Metformin exposure time was estimated as the quantity filled at each prescription collection, divided by the minimum daily dose used in clinical practice (500 mg), plus another 100 days to avoid falsely assumed termination of treatment due to non-compliance [7] .
The treatment-intensification cohort consisted of metformin-exposed patients, who added another GLD within the first 3 years and had at least one HbA 1c value recorded within 12 months before and within 3-6 months after the addon prescription date in a regional laboratory information system research database [6] (for patient flow, see electronic supplementary material [ESM] Fig. 1 ).
Add-on drugs Metformin add-on therapies examined were sulfonylurea (SU), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, other noninsulin GLDs and insulin. The first intensification drug defined add-on exposure and subsequent changes were ignored, an approach similar to intention-to-treat analyses. Add-on baseline HbA 1c , % 8.0 (7.3-9.2) 7.6 (7.0-8.6) 8.0 (7.2-9.2) 9.6 (7.9-11.0) 7.9 (7.2-9.1) 8.0 (7. Patients who received insulin add-on were younger, had higher baseline HbA 1c and more comorbidity (54 years, 9.6 (81 mmol/mol), and 27%).
HbA 1c reduction with add-on therapy Overall, median HbA 1c dropped from 8.0% (64 mmol/mol) at baseline to 6.8% (51 mmol/mol) within 2-6 months after commencement of addon therapy, corresponding to a reduction of 1.2% (13 mmol/mol). Absolute reductions were 1.2% (13 mmol/mol) (from 8.0 to 6.8% [64 to 51 mmol/mol]) for SU add-on, 0.8% (9 mmol/mol) (from 7.6 to 6.8% [60 to 51 mmol/mol]) for DPP-4 inhibitors, 1.3% (14 mmol/mol) (from 8.0 to 6.7% [64 to 50 mmol/mol]) for GLP-1 receptor agonists including 1.3% (14 mmol/mol) (from 7.9 to 6.6% [63 Table 2 ). Similar differences in attainment of an HbA 1c target <6.5% (<48 mmol/mol) appeared among type 2 diabetes patients aged <65 years without complications or comorbidities ( Fig. 2 and ESM Table 2 ), as well as in analyses restricted to the 2007-2012 period (n = 3,612 patients) (ESM Table 3 ), yet due to the smaller populations these estimates were statistically imprecise.
HbA 1c over calendar time The proportion of all metformin users who attained HbA 1c targets of <7% (<53 mmol/mol) and <6.5% (<48 mmol/mol), respectively, after add-on therapy increased from 46% and 26% in 2000-2003 to 59% and 29% in 2010-2012. This apparent time trend was associated with decreasing pre-intensification HbA 1c values over time (ESM Fig. 2 ). Corresponding proportions for metformin users aged <65 years without comorbidities who attained HbA 1c <6.5% (<48 mmol/mol) remained around 30% with a slightly decreasing tendency (ESM Fig. 3 
Discussion
Among real-world metformin users with short diabetes duration (0 to ≤3 years) who receive first add-on treatment, reduction in median HbA 1c was approximately 1% and comparable with that observed in randomised clinical trials [5] . Differences between add-on treatment regimens were modest, and HbA 1c reductions with add-on of DPP-4 inhibitors (0.8%, 9 mmol/mol), SU (1.2%, 13 mmol/mol) and GLP-1 receptor agonists (1.3%, 14 mmol/mol) were similar. Nonetheless, 41% of patients in the most recent years did not achieve an HbA 1c <7% (<53 mmol/mol) within 6 months.
The absolute HbA 1c reduction with insulin add-on therapy may be overestimated as it is positively correlated with baseline HbA 1c level, which was 1.5-2% (17-22 mmol/mol) higher [3] . In contrast, the absolute HbA 1c reduction was similar for SU and GLP-1 receptor agonist add-on, although the aRR for reaching HbA 1c <7% (<53 mmol/mol) was slightly higher with GLP-1 receptor agonists. Adjusted estimates for reaching HbA 1c targets with insulin tended to be lower, possibly related to some of the challenges that patients experience with early insulin administration in real life [8] . Nonetheless, our finding of similar HbA 1c levels achieved with insulin and other GLDs despite different HbA 1c baseline levels suggest that physicians choose effective therapy for patients with poor baseline glycaemic control, in accordance with guidelines [4, 8] .
Few, if any, comparable population-based studies have focused on early glycaemic control in metformin initiators after intensification. Across 11 US health systems, in 2005-2009, 48% achieved an HbA 1c <7% (<53 mmol/mol) among a subgroup of 3,135 patients who initiated monotherapy and then added an oral agent within 12 months [9] , which is comparable with the findings of the current study.
It is encouraging that an increasing share of patients reach HbA 1c <7% (<53 mmol/mol) after therapy intensification. This may be related to decreasing pre-intensification HbA 1c levels over time, likely reflecting closer follow-up and earlier treatment [6] . Nonetheless, it is of concern that more than 70% of early metformin users aged <65 years without recorded complications or comorbidities did not reach an HbA 1c level of <6.5% (<48 mmol/mol) as recommended by treatment guidelines and 25% still had an HbA 1c level of >7.4% (>57 mmol/mol) after intensification (upper quartile). One likely explanation is that half the patients in our cohort had HbA 1c ≥8.0% (≥64 mmol/mol) (median) and 25% had HbA 1c ≥9.2% (77 mmol/mol) (upper quartile) at the start of add-on therapy. Alternatively, the number, the dose or the efficacy of the drugs employed prior to intensification may not have fully matched the individual needs of each patient. As the greatest potential for prevention exists early in type 2 diabetes before complications have emerged [4] , future observational studies should examine possible reasons why many patients do not attain recommended HbA 1c targets following intensification.
Study strengths include a population-based design within the comprehensive Danish public healthcare system and, accordingly, our data reflect actual clinical practice in diabetes care. A limitation was that HbA 1c measurements within the right time frame were available only for two-thirds of potentially eligible patients. Moreover, prescription redemption is only a marker of actual drug consumption. Finally, although a wide range of confounding factors were assessed, imperfectly measured, unmeasured (e.g. BMI, beta cell function, lifestyle and socioeconomic measures) or unknown factors still may have affected risk estimates.
In conclusion, the observed glucose-lowering effects in real life are similar for different add-on drug options and comparable with those observed in randomised trials. Still, a substantial proportion of patients with type 2 diabetes in the community setting who receive intensification of metformin monotherapy do not achieve currently recommended HbA 1c targets.
